Reaction
Tumour Necrosis Factor Receptor-Associated Periodic Syndrome reporting signals
As of the last recalculation, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome appears in 60 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 1,573.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Canakinumab | 27 | 1,573.2 | 1,577.2 |
| Anakinra | 15 | 417.9 | 418.3 |
| Baricitinib | 7 | 285.0 | 285.2 |
| Tofacitinib Citrate | 7 | 209.6 | 209.7 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 128.4 | 128.5 |